March 13, 2013
07:00 EDT TSRX Trius Therapeutics should be bought ahead of data, says Piper Jaffray
Piper Jaffray recommends buying shares of Trius Therapeutics ahead of the ESTABLISH-2 study data later this month. The firm expects positive data to drive Trius shares higher and views the company as a potential acquisition candidate. Piper keeps an Overweight rating on the stock with an $11 price target.